Wednesday 24th July 2019
|Text too small?|
AFT Pharmaceuticals says it has successfully registered the intravenous form of its Maxigesic medication with Australia’s Therapeutic Goods Administration.
The intravenous product contains 1,000 milligrams of paracetamol and 300mg of ibuprofen in a 100 millilitre solution.
The company says it expects to sell the product in Australia during the year ending March 2020 and the registration “clears the way for regulatory filings in a number of other territories including but not limited to Mexico, South East Asia, Korea and the Middle East, all of which rely upon registration by key global reference regulators such as the TGA in Australia.”
AFT says the product is designed for post-operative pain relief for patients who can’t take oral pain relief.
No comments yet
Rio Tinto decision following strategic review of Tiwai
Contact says smelter closure is ‘disappointing’
South Port (SPN) Statement on NZAS Tiwai Point Aluminium Smelter Closure
Rio Tinto announcement on Tiwai Aluminium Smelter
Me Today announces equity raising to accelerate growth
Scott Technology Trading Update; Rising to the COVID Challenge
New non-binding indicative offer received from apvg, shareholder meeting deferred
U.S. Added 4.8 Million Jobs in June as Reopened Businesses Rehired
Auditors have a duty to be alert to fraud
Strong sales recovery but uncertainty remains over economic outlook and potential second wave of COVID-19